Enzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a report released on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Down 0.9 %

Shares of ENZ stock opened at $1.14 on Tuesday. Enzo Biochem has a 1-year low of $0.99 and a 1-year high of $1.50. The stock has a 50 day simple moving average of $1.12 and a 200-day simple moving average of $1.12.

Hedge Funds Weigh In On Enzo Biochem

A hedge fund recently raised its stake in Enzo Biochem stock. XTX Topco Ltd boosted its holdings in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,262 shares of the medical research company’s stock after acquiring an additional 13,735 shares during the period. XTX Topco Ltd owned 0.05% of Enzo Biochem worth $31,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.